Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Capricor Therapeutics (CAPR) to $20 from $43 and keeps an Overweight rating on the shares after the FDA issued a complete response letter for deramiocel in Duchenne muscular dystrophy. The firm believes Capricor could still win approval of cell therapy in 2026 and notes the company remains eligible for an $80M approval milestone from Nippon Shinyaku.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target lowered to $22 from $30 at Cantor Fitzgerald
- Capricor data in Q3 should support resubmission, says JonesResearch
- Capricor Therapeutics price target lowered to $24 from $77 at H.C. Wainwright
- Capricor Therapeutics’ Deramiocel: Overcoming Setbacks with Promising Phase 3 Trial and Long-term Efficacy Data
- Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection